欧洲的阿纳维克斯阿尔茨海默病药物申请被撤回,导致其库存下降. Anavex's Alzheimer's drug application in Europe was withdrawn, causing its stock to drop.

在该公司撤回了在欧盟的阿尔茨海默病药物Blarcamesine申请后, Anavex Life Sciences股价下跌. Anavex Life Sciences shares dropped after the company withdrew its application for Alzheimer's drug Blarcamesine in the European Union following negative feedback from regulators. 公司计划审查该机构的担忧, 并收集更多数据. The company plans to review the agency's concerns and gather more data. 与此同时,Anavex继续与美国食品和药物管理局讨论潜在的途径. Meanwhile, Anavex continues to discuss potential paths with the U.S. FDA.